Skip to main content

Table 4 Subgroup analysis: baseline demographics of patients with idiopathic pulmonary fibrosis before and after propensity score matching – intensive care unit respiratory hospitalizations without mechanical ventilation

From: Outcomes for hospitalized patients with idiopathic pulmonary fibrosis treated with antifibrotic medications

  Before propensity score matching After propensity score matching
No Rx (N = 1288) Pirfenidone/Nintedanib (N = 180) Std. Diff No Rx (N = 180) Pirfenidone/Nintedanib (N = 180) Std. Diff
Age group
45–64 168 (13.0%) 24 (13.3%) 0.010 30 (16.7%) 24 (13.3%) − 0.093
65–74 341 (26.5%) 65 (36.1%) 0.208 65 (36.1%) 65 (36.1%) 0.000
75 +  779 (60.5%) 91 (50.6%) − 0.201 85 (47.2%) 91 (50.6%) 0.067
Gender
Female 587 (45.6%) 52 (28.9%) − 0.352 55 (30.6%) 52 (28.9%) − 0.036
Male 699 (54.4%) 128 (71.1%) 0.352 125 (69.4%) 128 (71.1%) 0.036
Race
White 834 (64.8%) 121 (67.2%) 0.050 118 (65.6%) 121 (67.2%) 0.035
Black 93 (7.2%) 5 (2.8%) − 0.205 7 (3.9%) 5 (2.8%) − 0.062
Hispanic 131 (10.2%) 16 (8.9%) − 0.044 17 (9.4%) 16 (8.9%) − 0.019
Other 230 (17.9%) 38 (21.1%) 0.086 38 (21.1%) 38 (21.1%) 0.000
Census region
Midwest 386 (30.0%) 44 (24.4%) − 0.125 40 (22.2%) 44 (24.4%) 0.053
Northeast 173 (13.4%) 22 (12.2%) − 0.037 27 (15.0%) 22 (12.2%) − 0.081
South 606 (47.0%) 93 (51.7%) 0.094 90 (50.0%) 93 (51.7%) 0.033
West 123 (9.5%) 21 (11.7%) 0.068 23 (12.8%) 21 (11.7%) − 0.034
Baseline comorbidities
Cardiac Arrhythmia 542 (42.1%) 78 (43.3%) 0.027 80 (44.4%) 78 (43.3%) − 0.022
Congestive Heart Failure 508 (39.4%) 59 (32.8%) − 0.137 63 (35.0%) 59 (32.8%) − 0.047
Other Chronic Pulmonary Conditions 964 (74.8%) 115 (63.9%) − 0.240 118 (65.6%) 115 (63.9%) − 0.035
Depression 242 (18.8%) 29 (16.1%) − 0.071 27 (15.0%) 29 (16.1%) 0.031
Diabetes 509 (39.5%) 68 (37.8%) − 0.034 69 (38.3%) 68 (37.8%) − 0.011
Hypertension 996 (77.3%) 129 (71.7%) − 0.129 132 (73.3%) 129 (71.7%) − 0.037
Pulmonary Circulation Disorder 337 (26.2%) 59 (32.8%) 0.144 62 (34.4%) 59 (32.8%) − 0.035
Renal Failure 302 (23.4%) 39 (21.7%) − 0.042 37 (20.6%) 39 (21.7%) 0.027
Solid Tumor without Metastasis 183 (14.2%) 30 (16.7%) 0.067 27 (15.0%) 30 (16.7%) 0.046
Valvular Disease 344 (26.7%) 39 (21.7%) − 0.115 40 (22.2%) 39 (21.7%) − 0.013
Elixhauser comorbidity index
Mean (SD) 5.8 (3.2) 5.3 (2.8) − 0.166 5.4 (3.0) 5.3 (2.8) − 0.050
Median 5.0 5.0 −  5.0 5.0 − 
Q1, Q3 3.0, 8.0 3.0, 7.0 −  3.0, 7.0 3.0, 7.0 − 
N hospitalizations in baseline
0 749 (58.2%) 120 (66.7%) 0.176 115 (63.9%) 120 (66.7%) 0.058
1 324 (25.2%) 43 (23.9%) − 0.030 43 (23.9%) 43 (23.9%) 0.000
2 +  215 (16.7%) 17 (9.4%) − 0.215 22 (12.2%) 17 (9.4%) − 0.089
Year of hospitalization
2015 272 (21.1%) 18 (10.0%) − 0.311 17 (9.4%) 18 (10.0%) 0.019
2016 294 (22.8%) 39 (21.7%) − 0.025 36 (20.0%) 39 (21.7%) 0.041
2017 332 (25.8%) 57 (31.7%) 0.130 61 (33.9%) 57 (31.7%) − 0.047
2018 390 (30.3%) 66 (36.7%) 0.135 66 (36.7%) 66 (36.7%) 0.000
Reason for admission
Diseases of respiratory system 790 (61.3%) 89 (49.4%) − 0.240 85 (47.2%) 89 (49.4%) 0.044
Diseases affecting the interstitium 379 (29.4%) 88 (48.9%) 0.406 91 (50.6%) 88 (48.9%) − 0.033
All other reasons 119 (9.2%) 3 (1.7%) − 0.399 4 (2.2%) 3 (1.7%) − 0.040
Pulmonologist visit 728 (56.5%) 145 (80.6%) 0.535 150 (83.3%) 145 (80.6%) − 0.072
Smoker 652 (50.6%) 89 (49.4%) − 0.024 92 (51.1%) 89 (49.4%) − 0.033
Steroid use 725 (56.3%) 114 (63.3%) 0.144 114 (63.3%) 114 (63.3%) − 0.000
Oxygen use 765 (59.4%) 145 (80.6%) 0.431 143 (79.4%) 145 (80.6%) − 0.041